[Clinical and immunological studies in borderline mental disorders: problems and solutions]

Area of Science:

• Immunology
• Psychiatry
• Pharmacology

Context:

• Patients experiencing acute stress responses and short-term depressive disorders often present with immunological dysregulation.
• Tranquilizer therapy has been observed to suppress key components of cellular and humoral immunity, including T- and B-cell functions, antibody production, and lymphokine release.

Purpose:

• To investigate the immunological profiles of patients with stress-related and depressive disorders.
• To evaluate the efficacy of immunomodulating peptides as potential treatments for specific psychiatric conditions.

Summary:

• The study identified specific immunological disorders in patients with acute stress responses and prevalent short-term depressive disorders.
• Immunomodulating peptides, including myelopid and licopid, demonstrated differential therapeutic effects, with myelopid being most effective for anxiety and fear, and licopid for psychoasthenic disorders.
• Tranquilizers exhibited an inhibitory impact on cellular immunity (T- and B-cells), antibody formation, and lymphokine production.

Impact:

• The findings suggest that immunomodulating peptides represent a novel therapeutic strategy for mental health disorders.
• Psychotropic peptide therapy holds potential for developing new treatments for a range of psychiatric conditions, addressing both immunological and psychological symptoms.